1Hooper DC. Mechanisms of action of antimicrobials: focus on fluoroquinolones. Clin Infect Dis, 2001,32(Suppl 1):S9-S15.
2Weigel LM, Anderson GJ, Tenover FC. DNA gyrase and topoisomerase Ⅳ mutations associated with fluoroquinolone resistance in Proteus mirabilis. Antimierob Agents Chemother, 2002, 46 (8) :2582-2587.
3Ince D, Hooper DC. Quinolone resistance due to reduced target enzyme expression. J Bacteriol, 2003, 185(23):6883-6892.
4Visalli MA, Murphy E, Projan SJ, el al. AcrAB multidrug efflux pump is associated with reduced levels of susceptibility to tigecycline (GAR-936) in Proteus mirabilis. Antimicrob Agents Chemother, 2003, 47(2):665-669.
6Tran JH, Jacoby GA. Mechanism of plasmid mediated quinolone resistance. Proc Natl Acad Sci USA, 2002, 99(8): 5638-5642.
7Pierrat OA, Maxwell A. The action of the bacterial toxin microcin B17. Insight into the cleavage-religation reaction of DNA gyrase. J Biol Chem, 2003, 278(37):35016-35023.
8Martinez-Martinez L, Pascual A, Garcia I, et al. Interaction of plasmid and host quinolone resistance. J Antimicrob Chemother,2003, 51(4):1037-1039.
9Hata M. Suzuki M, Matsumoto M, et al. Cloning of a novel gene for quinolone resistance from a transferable plasmid in Shigella flexneri 2b. Antimierob Agents Chemother,2005, 49(2) : 801-803.
10Jacoby GA, Walsh KE, Mills DM, et al. qnrB, another plasmidmediated gene for quinolone resistance. Antimicrob Agents Chemother, 2006, 50(4) : 1178-1182.
